Thu, July 23, 2009
Wed, July 22, 2009
Tue, July 21, 2009
Mon, July 20, 2009
Sun, July 19, 2009
Fri, July 17, 2009
Thu, July 16, 2009
Wed, July 15, 2009
Tue, July 14, 2009
Mon, July 13, 2009
Fri, July 10, 2009
Thu, July 9, 2009
Wed, July 8, 2009
Tue, July 7, 2009
Mon, July 6, 2009
Fri, July 3, 2009
Thu, July 2, 2009
Wed, July 1, 2009
Tue, June 30, 2009
Mon, June 29, 2009
Fri, June 26, 2009
Thu, June 25, 2009
Wed, June 24, 2009
Tue, June 23, 2009
Mon, June 22, 2009
Sun, June 21, 2009
Fri, June 19, 2009
Thu, June 18, 2009
Wed, June 17, 2009
Tue, June 16, 2009
Mon, June 15, 2009
Fri, June 12, 2009
Thu, June 11, 2009
Wed, June 10, 2009
Tue, June 9, 2009
Mon, June 8, 2009
Sun, June 7, 2009
Fri, June 5, 2009
Thu, June 4, 2009
Wed, June 3, 2009
Tue, June 2, 2009
Mon, June 1, 2009
Sat, May 30, 2009
Fri, May 29, 2009
Thu, May 28, 2009
Wed, May 27, 2009
Tue, May 26, 2009
Mon, May 25, 2009
Fri, May 22, 2009
Thu, May 21, 2009
Wed, May 20, 2009
Tue, May 19, 2009
Mon, May 18, 2009
Fri, May 15, 2009
Thu, May 14, 2009
Wed, May 13, 2009

Quest PharmaTech Announces First Quarter Results


//health-fitness.news-articles.net/content/2009/ .. -pharmatech-announces-first-quarter-results.html
Published in Health and Fitness on , Last Modified on 2009-06-17 13:33:56 by Market Wire   Print publication without navigation


 TSX Venture: QPT EDMONTON, June 17 /CNW/ - Quest PharmaTech Inc. (TSX-V: QPT), a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced fiscal first quarter results for the period ended April 30, 2009. Highlights - Finalized and signed clinical trial agreements with centers in Edmonton and Toronto for initiation of SL052 Prostate Cancer clinical trial. Submissions made to respective research ethics boards; - Notified that positive research findings on SL052 photo-immunotherapy accepted for publication in peer-reviewed journal. The article, entitled, "Exploitation of Immune Response-Eliciting Properties of Hypocrellin Photosensitizer SL052-Based Photodynamic Therapy for Eradication of Malignant Tumors", will be published in an upcoming edition of Photochemistry and Photobiology; - Initiated evaluation and selection of second-generation formulations from several nanoparticle-based candidates to further adapt Hypocrellin-based photodynamic and sonodynamic therapy to a wider spectrum of clinical needs including cancer treatment; - Presented Company's updated profile to institutional and retail investors at BioFinance 2009 conference in Toronto. "The finalization of our clinical trial agreements moves us closer to realizing the potential for SL052 photodynamic therapy to become an effective treatment for prostate cancer with minimal collateral damage compared to conventional treatment approaches," stated Dr. Madi R. Madiyalakan, Chief Executive Officer at Quest. "Going forward, we believe that an increased focus on our oncology pipeline will yield more unique and potentially effective product candidates thereby creating greater value for Quest shareholders." Financial Results Net consolidated income for the three month period ended April 30, 2009 was $126,978 or $0.00 per share (April 30, 2008 - $74,809 or $0.00 per share). Research and development expenditures for the three month period ended April 30, 2009 totaled $119,316, while general and administrative expenses were $198,935 for the same period. As of April 30, 2009, the Company had cash and cash equivalents of $737,355. The Company also has debt of $500,000 in the form of a convertible debenture (exercisable at $0.25 and due on March 22, 2010). About Quest PharmaTech Inc. Quest is a publicly traded, Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions based on its unique photodynamic and sonodynamic therapy platforms. "TSX Venture Exchange has neither approved nor disapproved of the information herein." %SEDAR: 00008400E 
For further information: Dr. Madi R. Madiyalakan, Chief Executive Officer, Quest PharmaTech Inc., Tel: (780) 448-1400 Ext. 204, Email: [ madi@questpharmatech.com ], Internet: [ www.questpharmatech.com ]; Media and Investor Relations - Adam Peeler, The Equicom Group Inc., Tel: (416) 815-0700 Ext. 225, E-mail: [ apeeler@equicomgroup.com ]

Publication Contributing Sources